Antibody-Drug Conjugate Is Tolerable, Active in CLDN6-Positive Solid Tumors Including Ovarian Cancer
TORL-1-23 showed promising efficacy in CLDN6-positive advanced solid tumors, with varying ORRs across different doses, highest in ovarian cancer at 2.4 mg/kg. The ADC was well tolerated, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results